ERNAW
Ernexa Therapeutics Inc.
NASDAQ · Financial Services · Asset Management · US
$0.02
−15.02%Oct 6, 2026, 12:55 UTC
Ernexa Therapeutics announced that preclinical data on its ERNA-101 candidate will be presented at Nature Conferences' Next-Generation Cancer Therapeutics meeting co-hosted by MD Anderson Cancer Center in Houston on October 6, 2026.
Source:Sep 30, 2026, 12:32 UTC
Ernexa Therapeutics reported safety results for ERNA-101 across three IND-enabling studies, advancing toward a planned Q4 2026 IND filing.
Source:Sep 16, 2026, 20:56 UTC
Ernexa Therapeutics Inc. appointed Robert J. Spiegel, M.D. to its Board of Directors effective September 14, 2026.
Source:Sep 15, 2026, 12:42 UTC
Ernexa Therapeutics reported positive preclinical disease-modifying data for ERNA-201 in the collagen-induced arthritis model, supporting its engineered synthetic iMSC platform.
Source:Aug 10, 2026, 13:01 UTC
Ernexa Therapeutics appointed David Polinsky, a veteran biotech executive, to its board of directors as the company approaches the clinical stage.
Source:Jul 15, 2026, 11:50 UTC
Ernexa Therapeutics receives independent validation of its drug ERNA-101 in ovarian cancer models, showing complete tumor clearance and durable survival, ahead of planned clinical entry.